KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Payables (2018 - 2025)

Historic Payables for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $12.2 million.

  • Castle Biosciences' Payables rose 7930.98% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year increase of 7930.98%. This contributed to the annual value of $6.9 million for FY2024, which is 3279.12% down from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Payables is $12.2 million, which was up 7930.98% from $13.2 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Payables ranged from a high of $13.2 million in Q2 2025 and a low of $1.4 million during Q2 2021
  • For the 5-year period, Castle Biosciences' Payables averaged around $6.7 million, with its median value being $6.9 million (2024).
  • Per our database at Business Quant, Castle Biosciences' Payables plummeted by 4517.03% in 2021 and then surged by 20057.33% in 2023.
  • Quarter analysis of 5 years shows Castle Biosciences' Payables stood at $2.5 million in 2021, then surged by 85.82% to $4.7 million in 2022, then skyrocketed by 117.04% to $10.3 million in 2023, then crashed by 32.79% to $6.9 million in 2024, then skyrocketed by 76.95% to $12.2 million in 2025.
  • Its last three reported values are $12.2 million in Q3 2025, $13.2 million for Q2 2025, and $8.5 million during Q1 2025.